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Very early onset inﬂammatory bowel disease (VEO-IBD) is a
distinct form of IBD. Here, we review the current knowledge
of the genetic and immunologic basis of VEO-IBD, which
requires further investigation for improved and individual-
ized care.
Inﬂammatory bowel disease (IBD) is a multifactoral dis-
ease caused by dysregulated immune responses to
commensal or pathogenic microbes in the intestine,
resulting in chronic intestinal inﬂammation. An emerging
population of patients with IBD younger than 5 years of
age represent a unique form of disease, termed very early
onset IBD (VEO-IBD), which is phenotypically and geneti-
cally distinct from older-onset IBD. VEO-IBD is associated
with increased disease severity, aggressive progression,
and poor responsiveness to most conventional therapies.
Further investigation into the causes and pathogenesis of
VEO-IBD will help improve treatment strategies and may
lead to a better understanding of the mechanisms that are
essential to maintain intestinal health or provoke the
development of targeted therapeutic strategies to limit
intestinal inﬂammation and promote tissue repair. Here,
we discuss the phenotypic nature of VEO-IBD, the recent
identiﬁcation of novel gene variants associated with dis-
ease, and functional immunologic studies interrogating the
contribution of speciﬁc genetic variants to the develop-
ment of chronic intestinal inﬂammation. (Cell Mol Gastro-
enterol Hepatol 2015;1:462–476; http://dx.doi.org/10.1016/
j.jcmgh.2015.06.010)
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http://dx.doi.org/10.1016/j.jcmgh.2015.06.010Idisease, ulcerative colitis, and indeterminate colitis, is
a multigenetic and environmentally triggered disease
resulting in a dysregulated immune response to commensal
or pathogenic microbes found in the gastrointestinal
tract.1–7 Patients with IBD exhibit local and systemic im-
mune reactivity to various microbes, have signiﬁcant alter-
ations in the composition of intestinal commensal bacteria,and can become colonized with pathogenic or opportunistic
bacteria.8–15 The multifactorial nature and environmental
contribution to IBD is largely responsible for its increased
incidence over the last several decades.16 Added to the
complex nature of the disease, host genetics may play a
more prominent role in some subpopulations, particularly
in very young children (younger than 5 years of age) in
whom the disease is termed very early-onset IBD (VEO-
IBD).17,18 Although this is a heterogeneous population,
including some children with mild disease,19 patients with
VEO-IBD can present with a different disease phenotype,
including extensive colonic involvement and more severe
disease than older children and adults.17,20,21 In addition,
due to poor response to conventional therapies, severity of
inﬂammation, and greater duration of disease, there are
higher rates of morbidity in this population.20,22,23 Because
of the aggressive disease phenotype, early age of onset, and
strong family history of disease, some measure of VEO-IBD
is thought to be a monogenic disease, often involving
genes associated with primary immunodeﬁciencies.18,20,24
This was elegantly demonstrated with the discovery that
several IL10 (interleukin-10),25 IL10RA (interleukin-10
receptor, a), and IL10RB (interleukin-10 receptor, b)23 gene
mutations were associated with a phenotype of severe
perianal disease and colitis in infants with VEO-IBD.
Additional underlying immunodeﬁciencies or genetic dis-
orders may also present with an intestinal phenotype in
September 2015 Genetics and Immunology of VEO-IBD 463patients with VEO-IBD.20,24 These include, but are not
limited to, common variable immunodeﬁciency (CVID),
Wiskott-Aldrich syndrome (WAS), immunodysregulation,
polyendocrinopathy, and enteropathy, X-linked (IPEX) syn-
drome, and chronic granulomatous disease (CGD).17,20,22,26
Studying consanguinity and targeted genetic sequencing
has been an extremely valuable approach to allow the
identiﬁcation and characterization of genetic variants asso-
ciated with VEO-IBD. However, these approaches alone may
not identify novel and rare gene variants. Recent advances
in sequencing technology such as whole exome sequencing
(WES) have broadened our understanding of the patho-
genesis of VEO-IBD and resulted in further discoveries of
genes and pathways associated with the disease.26–30 The
genomic contribution of IBD has been extensively evaluated
through genomewide association studies (GWAS), and over
163 IBD-associated risk loci31 have been identiﬁed.
Several genes located within the IBD-associated loci are
critical for regulation of host defense, involving both the innate
and adaptive immune responses toward microbes.31 How-
ever, GWAS studies have been primarily performed in adult-
onset IBD and in children 10 years of age and older, whose
disease is most frequently a polygenic complex disease.
Furthermore, GWAS often do not capture rare variants, spe-
ciﬁcally those with a minor allele frequency of <5%. In
contrast, a proportion of patients with VEO-IBD have a
monogenic-driven disease ormultigenic disease enrichedwith
rare variants of the same or interacting immunologic path-
ways.32,23 Thus, as in the case of IL10RA and IL10RBdefects, the
development of intestinal inﬂammation in VEO-IBD patients
can be the direct result of defective immune responses.33
Although WES has revolutionized our ability to study
rare variants and to determine the genetic basis of disease,
understanding the relevance of the identiﬁed variants has
remained challenging. The individual patient’s phenotype
may be shaped by mode of inheritance, epigenetics, and
gene-gene interaction. Environmental modiﬁers such as the
intestinal microbiota, antibiotic exposure, infection, orTable 1.Features of Very Early Onset and Older Onset Inﬂamm
Feature VEO-I
Disease distribution
Predominately colonic
Ileal involvement <20%
Extensive disease at presen
Disease classiﬁcation
CD: 30%–35%
UC: 35%–59%
IC: 11%–22%
Positive family history 40%–50%
Genetic contribution Increased prevalence mono
Surgical intervention w71%
Other Therapeutic response to con
therapy: decreased
Consanguinity
CD, Crohn’s disease; IC, indeterminate colitis; UC, ulcerative cdiet also signiﬁcantly impact the disease phenotype.17,26,32
Because of the clinical presentation, often of severe dis-
ease, together with the challenge of identifying the unique
pathogenesis of the disease, there is currently no standard
of care in the evaluation and treatment for VEO-IBD pa-
tients. Identifying the driving forces in patients with
particularly severe early-onset disease may lead to group-
speciﬁc therapeutic approaches. Here we discuss the clin-
ical presentation of VEO-IBD patients, the identiﬁcation of
common gene variants associated with the disease, and
functional studies that have demonstrated how these vari-
ants may contribute to dysregulated immunologic homeo-
stasis in the intestine.
Clinical Presentation of Very Early
Onset Inﬂammatory Bowel Disease
Pediatric IBD has increased in incidence and prevalence,
and this phenomenon has included very young chil-
dren.16,33,34 VEO-IBD remains relatively uncommon,
approximately 6% to 15% of the pediatric IBD population is
younger than 6 years old, and disease in the ﬁrst year of life
is rare.16,34 A subset of patients with VEO-IBD present with
a phenotype that is distinct from older children and adults,
including extensive colonic disease (pancolitis) in which it is
frequently difﬁcult to differentiate ulcerative colitis from
Crohn’s disease, leading to a diagnosis of indeterminate
colitis (Table 1).20,34 At diagnosis, patients with VEO-IBD
are more commonly diagnosed with ulcerative colitis
(35% to 59%) as compared to older onset IBD (children
older than 6 years and adults) in which Crohn’s disease is
more prevalent (55% to 60%). In contrast, approximately
30% to 35% of VEO-IBD patients are diagnosed with
Crohn’s disease. Indeterminate colitis is also diagnosed
more often in patients with VEO (11% to 22%) as compared
to older onset IBD (4% to 10%).19,35–37
Although formal guidelines or standards of care do not
exist, disease evaluation of this population includesatory Bowel Disease
BD Older-Onset IBD
tation
Ileocolonic
Less extensive disease
at presentation
CD: 55%–60%
UC: 40%–45%
IC: 4%–10%
10%–20%
genic disorders <2 years Polygenic inheritance
w55%
ventional
olitis.
Table 2.Clinical Presentations and Laboratory Abnormalities of Very Early Onset Inﬂammatory Bowel Disease Patients
Type Gastrointestinal Manifestations Laboratory Abnormalities Pathology
B- and T-cell development
WAS (WASP) Microthrombocytopenia
Moderate-severe eczema
Recurrent or severe infections
Colitis: bloody diarrhea
Decreased platelets
Low marginal B cells, high transitional B cells,
elevated IgA, low IgM
Lymphopenia usually present, progressive
decline in T cells
CD4:CD8 ratio is normal.
Natural killer cell abnormalities
Crohn-like inﬂammatory process: cobblestone
appearance and inﬂammatory pseudo-
polyps38
Ulcerative colitis-like appearance reported:
extensive colitis with ulcerations39
Neutrophil and TH2 lymphocyte inﬁltration
Hypogammaglobulinemia,
X-lined (BTK) or AR
Diarrhea
Chronic infectious diarrhea (Giardia lamblia,
Salmonella species, Escherichia coli)
Crohn’s disease appearance
Perirectal abscess and ﬁstula
Hypogammaglobulinemia: defective B-cell
maturation secondary to mutations in BTk
B cells are severely decreased or absent in the
periphery
T cells or normal or increased
CD4: CD8 ratio is normal or decreased
Lack of plasma cells in lamina propria
Hyper IgM (CD40L, CD40,
AICDA, UNG)
Diarrhea, sclerosing cholangitis Low IgG, IgA
Normal or increased IgM
Impaired antibody response
LRBA deﬁciency Abdominal pain, diarrhea
Hypoalbuminemia may be present
Hypogammaglobulinemia40 Small bowel and colon: acute and chronic
inﬂammation can be seen41
Hyper IgE syndrome (STAT3,
DOCK8)
Susceptibility to infection (staphylococcal
infection)
Atopic dermatitis
Gastrointestinal manifestations most often
secondary to infection
Extremely elevated IgE levels
Low IgM
Decreased memory B cells
Neutropenia can be present
T cell lymphopenia
Histology and crypt destruction pattern most
resembles infectious agent42,43
Severe combined
immunodeﬁciency (ZAP70,
ITK, LCK)
Severe recurrent infection in infancy
Chronic diarrhea, malabsorption, and failure to
thrive
Oral and esophageal candidiasis
B and T cells are decreased in the peripheral
blood
T cells may have immature phenotype
Variants of severe combined immunodeﬁciency
can have less severe lymphopenia
B cells (CD19-HLA-DR) may be normal or
decreased
Defective IgG, IgA, normal IgM
Hypocellular lamina propria lacking plasma cells
or lymphocytes
Graft versus host disease-like process in colon
or small bowel can be present
X-linked severe combined
immunodeﬁciency (IL2RG)
Same Neutropenia
Absence of T cells and natural killer cells
Normal B cells
Same
Omenn syndrome (RAG1,
RAG2, Artemis, IL7Ra,
LIG4, ADA, CHD7)
Diffuse erythroderma
Hepatosplenomegaly
Lymphadenopathy
Chronic diarrhea
Failure to thrive
Hypereosinophilia and increased IgE
Can have oligoclonal T cells44 and reduced B
cells45
Graft versus host disease: numerous apoptotic
crypts cells in colon
Increase in lamina propria eosinophils46
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Table 2.Continued
Type Gastrointestinal Manifestations Laboratory Abnormalities Pathology
Common variable
immunodeﬁciency (TAC1,
ICOS, CD19, CD20, CD21,
CD81)
Heterogeneous presentation
Recurrent bacterial infection
Chronic infectious diarrhea
Helicobacter pylori infection common: atrophic
gastritis and pernicious anemia48
Malabsorption48
Granulomatous enteropathy
Decreased memory B cells
Defective plasma C
(CD27þ, CD19, HLA-DR)
T cells (CD2, CD3) usually quantitatively normal,
T cell abnormalities common
CD4:CD8 can be normal or decreased49
Antrum: nonspeciﬁc increase in lamina propria
lymphocytes; apoptotic cells47
Helicobacter pylori positive: atrophic gastritis
Small intestine: villous atrophy, increased
epithelial lymphocytosis47
Plasma cells absent or decreased50
Epithelial defects
ADAM 17 deﬁciency Present in neonatal period with watery diarrhea
that progresses to bloody diarrhea
Hypoplastic crypts in small bowel
Familial diarrhea (GUCY2C) Neonatal onset of watery diarrhea Neonatal electrolyte disturbances Crohn’s disease-like appearance
X-lined ectodermal dysplasia
and immunodeﬁciency
(IKBKG)
Diarrhea, failure to thrive
Susceptibility to infection
B-cell activation defects, can have
hypogammaglobulinemia
Natural killer cell abnormalities
Enterocolitis with villous atrophy and epithelial
shedding51
TTC7A deﬁciency Severe diarrhea
Colitis presentation
Can have low immunoglobulin levels
Defect in vaccine response
Small bowel: villous atrophy
Colon: apoptosis
Klinder syndrome (FERMT1) Blistering skin defects and hyperkeratosis of
palms and soles
Can have eosinophilia Intestinal epithelium: focal detachment of
epithelium
Ulcerations
Dystrophic epidermolysis
bullosa (COL7A1)
Bloody diarrhea Colon: apoptosis
Severe colitis
Phagocyte defects
Chronic granulomatous
disease (CYBB: x-linked,
CYBA, NCF1, NCF2, NCF4,
RAC1)
Recurrent infection/abscesses
Perianal disease/ﬁstula
Esophageal and gastric outlet obstruction
Colitis
Abnormal respiratory burst Transmural and discontinuous inﬂammation,
with aphthous or serpiginous ulcers can be
seen, can be indistinguishable from Crohn’s
disease52
Intestinal granulomas, increased compared to
Crohn’s disease
Crohn’s disease-like lesions in the small bowel
Fistulas, longitudinal ulcers, stenosis
Ulcerative colitis appearance
Pigmented macrophages
Glycogen storage disease type
1 (SLC37A4)
Crohn’s disease presentation
Perianal disease and oral manifestations
Neutropenia
Neutrophil dysfunction
Perianal disease and oral manifestations may
appear
Leukocyte-adhesion deﬁciency
(ITGB2)
Defective chemotaxis, phagocytosis, and
bacterial killing
Abnormal respiratory burst
Increased peripheral granulocytes Colonic disease, adhesions, and strictures may
be present
Genetic variants in the IL-10/IL-10R pathway and regulatory T cells
IL-10 ligand and IL10RA and
IL10RB
Most frequently neonatal onset of disease,
bloody diarrhea
Perianal ﬁstula
Arthritis
Abscesses
Abnormal phosphorylation of STAT3 mediated
by IL-10
Ileal and colonic inﬂammation, ulcerations,
inﬂammatory inﬁltrates
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Type Gastrointestinal Manifestations Laboratory Abnormalities Pathology
X-linked immune
dysregulation,
polyendocrinopathy,
enteropathy (FOXP3,
STAT1)
Polyendocrinopathy
Recurrent infection
Severe enteropathy with watery diarrhea, can
be bloody
Lack of CD4þ, CD25þ, FOXP3þ regulatory
T cells
Elevated IgA and IgE
Normal B cell numbers
Eosinophilia
Extensive villous atrophy
Features of graft versus host disease with
apoptosis of epithelial cells
Presence of antienterocyte antibodies along
brush border of duodenum53
Lymphocytic, neutrophilic and eosinophilic
inﬁltration of crypts and crypt abscesses53
Colitis
Hyperimmune or autoinﬂammatory
Mevalonate kinase deﬁciency
(MVK)
Diarrhea
Abdominal pain, emesis
Recurrent fevers
Hyperimmunoglobulinemia D
Natural killer cell dysfunction
Elevation of inﬂammatory markers erythrocyte
sedimentation rate, C-reactive protein
Colon: ulcers, cellular inﬁltrate, apoptosis54
Familial Mediterranean fever
(MEFV)
Recurrent fevers, diarrhea
Abdominal pain
Joint pain
Amyloidosis
Vasculitis
Peritonitis
Recurrent oral aphthae
Elevated white blood cell count and
inﬂammatory markers
Small bowel inﬂammation55
Changes similar to Crohn’s disease with
chronic inﬂammation and ulceration may
appear56
X-linked lymphoproliferative
syndrome 1 (XLP1)
(SH2D1A), defective SLAM
Epstein-Barr virus triggered hemophagocytic
lymphohistiocytosis
Hypogammaglobulinemia
Poor antibody response
Unspeciﬁed colitis, may have absent plasma
cells
X-linked lymphoproliferative
syndrome 2 (XLP2, XIAP)
Epstein-Barr virus triggered hemophagocytic
lymphohistiocytosis
Clinical features similar to observed in Crohn’s
disease
Hypogammaglobulinemia
Decreased natural killer cells can be present
Features similar to Crohn’s disease
Apoptosis can be seen
Hermansky-Pudlak syndrome
(IBD phenotype
involvement: HPS1, HSP4,
HSP6)
Oculocutaneous albinism
Easy bruising
Inﬂammatory bowel disease symptoms of
abdominal pain, diarrhea, bloody can be
present
Normal platelet count
Prolonged bleeding time
Platelet dysfunction
Broad ulcers
Brown granular pigmentation
Nonnecrotizing granulomas
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September 2015 Genetics and Immunology of VEO-IBD 467laboratory, radiologic, and endoscopic evaluation (Table 2).
A diagnosis at a very young age should trigger concern for a
monogenic-driven disease, particularly in IBD diagnosed
when the patient is younger than 2 years of age. Further-
more, extensive family history, including a history of disease
in male family members (such as in X-linked disease) or a
history of infection, skin disease, or autoimmunity can
help guide the appropriate laboratory screening. The
laboratory studies should include not only the routine
screening used for IBD diagnosis but also an immunologic
evaluation. This includes vaccine titers, immunoglobulin
proﬁles, analyses of B- and T-cell function, and a dihydro-
rhodamine ﬂow cytometry assay, and if necessary more
targeted phenotyping and functional proﬁling of the sys-
temic and mucosal immune system. As shown in Table 2,
these studies may point to an underlying defect such as
neutropenia, which may represent a monogenic disorder
causing functional defects in neutrophils such as glycogen
storage disease type 1b, leucocyte adhesion deﬁciency, or
congenital neutropenia.
Genetic Variants Associated With
VEO-IBD and Their Immunologic
Consequences
Monogenic diseases that can present with the phenotype
of intestinal inﬂammation include those that cause defects
of intestinal epithelial barrier function, phagocyte bacterial
killing, development and function of the adaptive immune
system, and hyper- or autoimmune-inﬂammatory disor-
ders.32 These genetic alterations may differentially inﬂuence
the development and progression of intestinal inﬂammation,
so these patients will likely exhibit signiﬁcant heterogeneity
in their responsiveness to therapeutic interventions. We will
discuss what we have learned from mouse models and
translational patient-based studies, which should be
considered when developing therapeutic strategies for these
unique patient populations.Genetic Variants Inﬂuencing Intestinal Epithelial
Barrier Function
Mutations in genes associated with maintaining integrity
of the intestinal epithelial barrier can present with intestinal
inﬂammation in patients with VEO-IBD. These include loss-
of-function mutations in ADAM17 (A disintegrin and
metalloproteinase domain 17) resulting in ADAM17 deﬁ-
ciency,57,58 in IKBKG (inhibitor of k light polypeptide gene
enhancer in B cells, kinase of, g; encoding nuclear factor-kB
essential modulator: NEMO) resulting in X-linked ecto-
dermal dysplasia and immunodeﬁciency,59 in COL7A1
(collagen, type VII, a1) resulting in dystrophic epi-
dermolysis bullosa,60 FERMT1 (Fermitin family homolog 1)
resulting in Kindler syndrome,61–63 and TTC7A (tetra-
tricopeptide repeat domain-containing protein 7A,29 or
gain-of-function mutations in GUCY2 (guanylate cyclase 2)
resulting in familial diarrhea.17,64 Mutations in these genes
may all lead to an impairment of the intestinal epithelial
barrier through distinct pathways, such as limiting epithelialregeneration (ADAM17),65 loss of signaling pathways
involved in gene expression (IKBKG),66,67 altered cell
adhesion, barrier formation, apoptosis (COL7A1, FEMT1, and
TTC7A),29,60–63 or impaired bacterial sensing and ion ho-
meostasis (GUCY2).17,64 The intestinal histology of patients
with epithelial defects can be helpful in distinguishing the
disease from other causes of intestinal inﬂammation. For
example, patients with IKBKG (NEMO) defects may have
villous atrophy or epithelial cell shedding on pathologic
examination.68 In contrast, histology in patients with
ADAM17 mutations may demonstrate hypoplastic crypts in
the small bowel secondary to a low rate of epithelial pro-
duction, as ADAM17 is necessary for transforming growth
factor-a to be cleaved from the cell membrane.69,70
The intestinal barrier is necessary to maintain a physical
separation between commensal bacteria and the mamma-
lian immune system, and a breakdown in this barrier
through multiple distinct pathways can directly promote
chronic intestinal inﬂammation.1,3 In addition to the genes
we have listed, intestinal barrier function is maintained
through a number of physical and biochemical structures,
including mucus production, intestinal epithelial cell tight
junction proteins, immunoglobulin A (IgA), and antimicro-
bial peptides (Figure 1). In mice, chemical disruption of the
intestinal barrier through administration of dextran sodium
sulfate in drinking water results in dissemination of
commensal bacteria and activation of the innate immune
system.71 Chronic exposure to dextran sodium sulfate can
lead to activation of the adaptive immune system and to the
development of proinﬂammatory, commensal bacteria-
speciﬁc B- and T-cell responses,8,72 which are similar to
those observed in IBD patients.8,73
Intestinal epithelial cells play an important role in
directly regulating immunologic homeostasis in the intes-
tine, as mice with intestinal epithelial cell lineage–speciﬁc
deletion of factors regulating the nuclear factor-kB pathway,
including NEMO and IkB kinase-b, have an increased sus-
ceptibility to develop chronic intestinal inﬂammation.66,67
Although we know that loss of intestinal barrier function
can directly cause intestinal inﬂammation, additional mouse
models and translational patient-based approaches are
required to further deﬁne how mutations in these genes
speciﬁcally lead to a breakdown in the barrier, and whether
we can develop more targeted therapies to restore barrier
integrity and limit chronic inﬂammation.Genetic Variants Impairing Development of the
Adaptive Immune System
Several genetic variants can alter the development or
function of adaptive immune cells in a cell intrinsic or
extrinsic manner.32 Defects that affect development or
function of B cells and T cells occur with loss-of-function
mutations in recombination-activating genes (RAG1 or
RAG2) or the IL-7R (IL7R) causing Omenn syndrome, or the
PTEN (phosphatase and tensin homolog) gene causing
PTEN syndrome. Defects in RAG1, RAG2, or IL-7R can cause
cell-intrinsic defects in the development of both T cells and
B cells by blocking either early lymphocyte survival or
Figure 1. Intestinal epithelial barrier function plays an essential role in maintaining intestinal health. Physical and
biochemical barriers, including tight junctions, immunoglobulin A, antimicrobial peptides, mucus, and the ILC3-IL-22 pathway,
maintain intestinal epithelial barrier function. This is essential to maintain anatomic segregation between commensal bacteria
and the mammalian immune system. Loss of this physical segregation can promote dysregulated innate and adaptive immune
cell responses. Identiﬁed genetic variants that result in a loss or gain of function mutation and are associated with very early
onset inﬂammatory bowel disease are noted in orange boxes.
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Defects in B-cell development lead to an absence of circu-
lating mature B cells and antibody production, which have
been linked to an IBD phenotype.77 This includes agam-
maglobulinemia, which can also occur in X-linked agam-
maglobulinemia78 and CVID, a complex and heterogeneous
disease, with the responsible mutations known for only a
minority of cases.79 Recently, one candidate gene causing
CVID and potentially contributing to intestinal inﬂamma-
tion was identiﬁed using WES as a loss-of-function muta-
tion in LRBA (lipopolysaccharide-responsive beige-like
anchor), resulting in multiple defects in immune cell
populations.40
Related to CVID, antibody deﬁciencies associated with
IBD manifestations include IgA deﬁciency and severe com-
bined immunodeﬁciency, which can be secondary to multi-
ple variants that inﬂuence the development or function of
the adaptive immune system (including RAG1, RAG2, JAK3,
CD45, CD3G, ZAP70, ADA, DCLRE1C).32,77,80 Omenn syn-
drome, a recessive form of severe combined immunodeﬁ-
ciency, involves abnormal development of B cells and T
cells, and can also be associated with intestinal disease as
well as severe eczematous rash.80,81 In these patients, lab-
oratory studies indicate increased oligoclonal T cells and
reduced B cells, and histologic examination can show an
intestinal graft versus host appearance.82,83 Conversely,
overproduction of speciﬁc immunoglobulins, such as hyper
IgM, hyper IgE syndrome (resulting from a loss of function
mutation in DOCK8) can also result in intestinal inﬂamma-
tion and an IBD phenotype.84
It is currently unclear exactly how these selective
impairments of the adaptive immune system can manifest
in intestinal inﬂammation. There is a potential involvement
of altered regulatory pathways or chronic infections
with pathogenic and opportunistic microbes. Therefore,
additional lines of study are required to further
interrogate the link of these mutations to intestinal
inﬂammation.Wiskott-Aldrich syndrome results from a loss-of-
function mutation in the Wiskott-Aldrich syndrome pro-
tein (WASP), and patients can exhibit thrombocytopenia,
eczema, immune deﬁciencies, and intestinal inﬂamma-
tion.85 The clinical manifestation of VEO-IBD patients
with this genetic defect can be pancolitis in addition to
other autoimmune processes. WASP is a critical cyto-
skeleton protein expressed in hematopoietic cells, and it
is required for the normal development and function of
multiple cell types.86,87 WASP is critical for peripheral B-
cell development and function and thus the ability to
respond to antigens.88,89 Laboratory studies in these pa-
tients may show thrombocytopenia, low IgM levels, low
marginal B cells, and lymphopenia.90 Nguyen et al91
identiﬁed that intestinal inﬂammation in WASP-deﬁcient
mice was critically dependent upon inﬂammatory T cells,
which may result from impaired development of regula-
tory T cells (Tregs) in the thymus and periphery.92 Sur-
prisingly, these defects are likely occurring in a cell-
extrinsic manner, as the absence of WASP in cells of the
innate immune system directly contributed to the devel-
opment of inﬂammatory T-cell responses in mice.93
The causes of intestinal inﬂammation in other similar
patient populations are less well understood, but defects in
regulatory T cells, IgA, and abnormal selection of T-cell and
B-cell speciﬁcities likely contribute. Additional immunologic
analyses and mouse models, such as those we have
described, are needed to deﬁne the causes of disease further
and to develop potential therapeutic options in these patient
populations.Genetic Variants Impairing Regulatory T Cells
Defects in regulatory T cells can clinically present as
colonic disease as well as an enteropathy. IPEX syndrome is
most often secondary to mutations of the forkhead box
protein 3 (FOXP3) gene, a transcription factor that is
essential for the development and immunosuppressive
September 2015 Genetics and Immunology of VEO-IBD 469activity of CD4 Foxp3þ Tregs.94,95 There are over 20 mu-
tations in FOXP3 that have been identiﬁed in patients with
IPEX,96 and patients frequently present with neonatal se-
vere secretory diarrhea, failure to thrive, infection (due to
defects in immunoregulation), skin rash, insulin-dependent
diabetes, thyroiditis, cytopenias, and other autoimmune
disorders.94,95 Tregs are absent or dysfunctional in these
patients, and in the intestine histologic analyses may reveal
inﬁltration of inﬂammatory cells in the lamina propria and
submucosa of the small bowel and colon as well as changes
in the mucosa of the small bowel.94 Other genetic defects
have been found to cause IPEX-like disease, including loss-
of-function mutations impacting IL-2/IL-2R interactions,
STAT5b (signal transducer and activator of transcription
5b), and ITCH (itchy E3 ubiquitin protein ligase), or gain-
of-function mutations in STAT1, all of which critically in-
ﬂuence the development and function of Tregs.81 Further,
Zeissig et al97 have recently identiﬁed in VEO-IBD a novel
loss of function mutation in CTLA4 (cytotoxic T
lymphocyte-associated protein 4), a surface molecule of
regulatory T cells that directly suppresses effector T-cell
populations.
The mechanisms by which regulatory T cells limit in-
testinal inﬂammation are well characterized in mice. TregsFigure 2. Regulatory T cells, interleukin-10 (IL-10) and I
commensal bacteria. Regulatory T cells (Treg) can differentiate
intestinal commensal bacteria through multiple mechanisms, i
sequestering of growth factors. Further, IL-10production bymulti
from myeloid cells to limit intestinal inﬂammation. ILC3 can also d
interactions. iTreg, inducible regulatory T cell; nTreg, natural regul
of function mutation and are associated with very early onset inﬂcan develop in the thymus as “natural Tregs” and directly
contribute to limiting proinﬂammatory T cells in the intes-
tine.98 The composition of commensal bacteria inﬂuences
the repertoire of Tregs,98 and commensal bacteria-speciﬁc
“induced Tregs” can also be generated in the periphery af-
ter sampling of commensal bacteria by dendritic cells in the
intestine and migration to the mesenteric lymph node
(Figure 2).1,5,99,100 Once generated, Tregs can then promote
intestinal homeostasis through direct regulation of innate
and adaptive immune cell responses to commensal bacteria,
a process that involves cytokine production, direct cell-cell
contact (in part through CTLA4), and sequestering of
growth factors.1,5,99
Consistent with a major role for Tregs in limiting
proinﬂammatory immune cell responses to commensal
bacteria, mice deﬁcient in IL-2 or FoxP3 develop signiﬁ-
cantly less intestinal inﬂammation when maintained in
germ-free versus conventional housing conditions, but they
exhibit comparable levels of systemic autoimmunity.101,102
Recent evidence also suggests that the balance of tissue-
speciﬁc IL-23 and IL-33 expression in mice is critical for
regulating the function of Tregs in the intestine and chronic
inﬂammation,103 although the role of these pathways in
human VEO-IBD has not been examined.LC3 critically limit dysregulated immune responses to
in the thymus or periphery and limit immune cell responses to
ncluding cytokine production, direct cell-to-cell contact and
ple cell types candirectly promote anti-inﬂammatory responses
irectly limit proinﬂammatory T cells through MHCII-dependent
atory T cell. Identiﬁedgenetic variants that result in a loss or gain
ammatory bowel disease are noted in orange boxes.
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10 Receptor Pathway and Related Cytokine
Family Members
Homozygous loss of function mutations in IL10 ligand
and receptors IL10RA and IL10RB are associated with sig-
niﬁcant intestinal inﬂammation, particularly in neonatal or
infantile VEO-IBD, with a phenotype of severe enterocolitis
and perianal disease.23,25 In addition, compound heterozy-
gote loss of function mutations of IL10RA have been re-
ported with neonatal Crohn’s disease and enterocolitis.104
IL-10 is an anti-inﬂammatory cytokine secreted by a vari-
ety of cells, including dendritic cells, natural killer (NK)
cells, eosinophils, mast cells, macrophages, B cells and CD4þ
T cell subsets (including TH2 cells, TH1 cells, TH17 cells and
Treg).105,106 IL-10 maintains homeostasis through sup-
pression of an excessive proinﬂammatory response and
exerts its effect through binding to the IL-10 receptor, IL-
10R, which is a tetrameric complex.107 It is composed of 2
distinct chains, 2 molecules of IL-10R1 (a chain) and 2
molecules of IL-10R2 (b chain).108 IL-10 binding to IL-10R
activates the JAK1/STAT3 cascade, which subsequently
limits proinﬂammatory gene expression.108 In addition to
intestinal inﬂammation, IL-10 defects are associated with
arthritis, folliculitis, and a predisposition to lym-
phoma.104,109 Given that the defects in IL-10-IL-10R in-
teractions predominantly inﬂuence the immune system, a
potential treatment for these patients is successful
hematopoietic stem cell transplantation.110 Although this
can be challenging and typically requires an HLA-identical
donor, there has been recent success reported with hap-
loidentical stem cell transplantation, however nonengraft-
ment complications can occur.111
An essential role for IL-10 in limiting intestinal inﬂam-
mation was demonstrated when IL-10 deﬁcient mice were
generated and found develop severe spontaneous colitis,112
and subsequent studies by Sartor et al113 identiﬁed that the
intestinal inﬂammation in IL-10-deﬁcient mice was entirely
dependent upon the presence of commensal bacteria.
Therefore, IL-10 plays a critical role in limiting dysregulated
immune cell responses to intestinal commensal bacteria
(Figure 2). The exact cellular sources and targets of IL-10
that contribute to the maintenance of intestinal homeosta-
sis have been less well deﬁned until the recent development
of mice that permit conditional deletion of IL-10 and IL-10R.
These critical studies have revealed an essential role of
regulatory T cell-intrinsic IL-10 expression in preventing
intestinal inﬂammation in mice.114,115 Further, it was
recently demonstrated that IL-10R expression on myeloid
cells in mice is critical to elicit anti-inﬂammatory responses
and limit T cell-dependent intestinal inﬂammation.116,117
Critically, patients with loss-of-function mutations in
IL10RA or IL10RB also exhibited an impaired ability to
differentiate anti-inﬂammatory myeloid cells in vitro, and
rather exhibited increased proinﬂammatory properties,
such as elevated expression of IL-6, IL-12, tumor necrosis
factor-a (TNFa), MHCII (major histocompatibility complex
class II), and costimulatory molecules.116 Although mouse
models have provided invaluable insight into human healthand disease, it should be noted that mice deﬁcient in Il10 do
not completely replicate the phenotypes of humans with
loss-of-function mutations in IL10, likely due to many con-
founding factors.
IL-22 is a cytokine that is related to IL-10, shares the
IL-10R2 chain with a unique IL-22R1, signals through pre-
dominantly STAT3, and also plays a critical role in mediating
intestinal homeostasis.118 However, unlike IL-10, the func-
tional IL-22R is restricted to predominantly non-
hematopoietic cells; in the intestine, IL-22 acts almost
exclusively on intestinal epithelial cells to mediate innate
immunity and intestinal barrier function (Figure 1).118 IL-22
can be produced by TH17 cells, and more recently has been
identiﬁed to be predominantly expressed by a previously
unrecognized cell type of the innate immune system, termed
group 3 innate lymphoid cells (ILC3).118,119 This break-
through in immunology has led to the identiﬁcation of other
members of the innate lymphoid cell (ILC) family, including
group 1 ILCs that express T-bet and proinﬂammatory cy-
tokines TNFa and interferon-g, and group 2 ILCs that ex-
press GATA3 and type 2 cytokines IL-4, IL-5, IL-9, IL-13, and
amphiregulin.119,120
The ILC family exhibits a heterogeneity comparable to
that of differentiated CD4 T-cell subsets, and plays a pro-
found role in regulating intestinal health and disease in
mouse models.118–120 Critically, recent reports suggest that
ILC3 is a dominant source of IL-22 in the intestine of healthy
humans, and that dysregulated ILC responses are observed in
adult patients with IBD.121–127 Further, we have also recently
identiﬁed that ILC3 expresses MHCII, and that selective
deletion of MHCII on ILC3 results in dysregulated CD4 T-cell
responses and spontaneous intestinal inﬂammation.122
MHCIIþ ILC3 selectively induces cell death of proin-
ﬂammatory, commensal bacteria-speciﬁc CD4 T cells in the
intestine; critically, we observed that MHCII was reduced on
ILC3 from intestinal biopsy tissues of pediatric IBD patients
versus non-IBD controls, and that this was inversely corre-
lated with the level of proinﬂammatory TH17 cells.
128
Despite these advances, ILC and IL-22 responses have yet
to be explored in VEO-IBD. Given the importance of these
pathways in mediating intestinal health and disease, it is
likely that the genetic variations associated with VEO-IBD,
such as IL7/IL7R, may differentially inﬂuence ILC responses.
Genetic Variants Inﬂuencing Bacterial
Recognition and Clearance
Chronic granulomatous disease (CGD) is a result of
defective intestinal phagocytes, speciﬁcally the granulocytes
responsible for bacterial killing and clearance.129 The
NADPH oxidase complex is responsible for killing ingested
microbes through its production of the respiratory burst.
Mutations in any part of the complex molecules (CYBB,
CYBA, NCF1, NCF2, NCF4) can result in intestinal inﬂam-
mation as well as autoimmune disease.130,131 Intestinal
inﬂammation can be observed in as many as 40% of
patients with CGD.52,132–134
Several variants have been associated with VEO-IBD, in
particular defective NCF2 (neutrophil cytosolic factor 2)
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toxin substrate 2).135 These patients can present in the
neonatal or ﬁrst year of life with colitis, severe ﬁstulizing
perianal disease, and stricturing.135 Histology frequently
demonstrates multiple granulomas that may not have
associated inﬂammatory change.26 Critically, a recent study
by Dhillon et al136 identiﬁed that heterozygous loss-of-
function mutations in components of the NADPH oxidase
complex can determine susceptibility to VEO-IBD, without
directly causing overt immunodeﬁciency. Other neutrophil
defects that are associated with VEO-IBD include leukocyte-
adhesion defect due to mutation in ITGB2 (integrin,
b2).137,138 These patients can present with an IBD pheno-
type, history of bacterial infection, and laboratory studies
remarkable for increased peripheral granulocytes.139
Glycogen storage disease type 1b, with hallmark features
of neutropenia and neutrophil granulocyte dysfunction, can
present with intestinal inﬂammation.140
The reasons why CGD and other bacterial processing
defects may manifest in intestinal inﬂammation are poorly
understood and warrant additional research. It is possible
that the causes include bacterial overgrowth or dysbiosis in
the intestine, dysregulated activation of the innate and
adaptive immune system, or both.
Further, the therapies used to treat such patients need to
be carefully considered. For example, anti-TNFa therapy is
contraindicated in CGD; although it is effective for intestinal
disease, it can increase the risk of severe infections in these
patients.141 Other therapies include leukine, antibiotics, and
allogenic hematopoietic stem cell transplantation, which
have demonstrated some success.142 Recent evidence sug-
gests that IL-1R antagonists may be a particularly attractive
approach to limit disease in mouse models and patients
with CGD by restoring autophagy and directly limiting
inﬂammation.143Hyper- and Autoimmune-Disorders
Several autoimmune diseases have been linked with in-
testinal inﬂammation in children with VEO-IBD. These
include mevalonate-kinase deﬁciency,144 familial Mediter-
ranean fever (FMF),145,146 Hermansky-Pudlak syndrome,147
and X-linked lymphoproliferative syndrome (types 1
and 2).28,148,149 These diseases occur due to loss-of-function
mutations in an enzyme critical for metabolism (mevalonate-
kinase deﬁciency), cytoskeletal proteins (familial Mediter-
ranean fever), proteins involved in organelle fusion or
biogenesis (Hermansky-Pudlak syndrome), or proteins
involved in cell signaling or apoptosis (X-linked lympho-
proliferative syndrome). Although there are many additional
clinical manifestations in these patients, 20% of patients
with X-linked lymphoproliferative syndrome that have a
loss-of-function defect in the gene X-linked inhibitor of
apoptosis protein (XIAP), present with VEO-IBD.150
XIAP is involved in nucleotide-binding oligomerization
domain-containing protein 2 (NOD2)-mediated nuclear
factor-kB signaling, so these children may have an impaired
ability to sense bacteria. In addition, as an inhibitor of
apoptosis, it prevents apoptosis of activated T cells, thusallowing for expansion and survival of T cells in response to
pathogens.151,152 Therefore, in XIAP deﬁciency, due to the
inability to clear pathogens, there is a hyperinﬂammatory
state with increased production of cytokines resulting in an
IBD phenotype.150,152 Children with these mutations can
present with severe colonic and perianal ﬁstulizing dis-
ease;28,153 of great concern, Epstein-Barr virus infection can
result in fatal hemophagocytic lymphohistiocytosis.153
This was not an exhaustive description of the rare
genomic drivers of VEO-IBD, but it highlights the different
components of the immune system, including innate and
adaptive responses, involved in this disease. Treatments
guided toward the speciﬁc defect, such as IL-1 antagonists,
colchicine, hematopoietic stem-cell transplantation, or leu-
kine can be used if the defect is determined. Additionally,
monitoring for potential complications associated with a
genetic defect is essential, such as in XIAP, IL-10 gene var-
iants, and CGD. In addition to these monogenic diseases,
VEO-IBD has been shown to have a high degree of genetic
heterogeneity. It is therefore likely that there are more
pathways involved in VEO-IBD, and the outcome of thera-
peutic intervention can be improved through further study
and identiﬁcation of the associated variants. Using next-
generation sequencing technology such as WES can
improve the detection of variants and the diagnosis of dis-
ease. Further, there is an urgent need to also directly
translate genes to function and to functionally proﬁle the
immunologic signiﬁcance of known genetic variations in
intestinal inﬂammation.Perspective and Future Directions in
Genetic and Immunologic Analyses
of Very Early Onset Inﬂammatory
Bowel Disease
To advance our understanding of VEO-IBD, new
sequencing technology must be used to completely survey
the genetic landscape of this disease. Immunologic studies
spanning basic mouse models and translational patient-
based approaches are required to determine the contribu-
tion of those genetic variations to human disease. Given that
dysregulated interactions between the immune system and
commensal bacteria underlie the pathogenesis of intestinal
inﬂammation, it is also important to include analyses of the
composition and function of the microbiome. Given that
these patient populations are studied worldwide and
sometimes in small numbers, an international registry
containing the genetic, immunologic, and environmental
data of VEO-IBD patients could prove beneﬁcial in our goal
of better understanding the effects of different variants
within known genes and identifying new gene defects that
cause IBD through the study of mutations that arise in the
same genes of multiple unrelated individuals. With an
increased understanding of the disease processes operating
in VEO-IBD, we can begin to individualize therapies to the
speciﬁc patient or patient groups, as well as employ un-
conventional therapies that are not routinely part of the IBD
therapeutic arsenal. These approaches could provide a
472 Kelsen et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5roadmap to establishing a standard of care for this disease
and improving patient quality of life.References
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